By Dr Scott Ledger

Journal articles

Agbosu EE; Ledger S; Kelleher AD; Wen J; Ahlenstiel CL, 2022, 'Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection', Pharmaceutics, 14, http://dx.doi.org/10.3390/pharmaceutics14071352

Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL, 2022, 'Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract', International Journal of Molecular Sciences, 23, http://dx.doi.org/10.3390/ijms23052408

Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD, 2018, 'RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency', Retrovirology, 15, pp. 67, http://dx.doi.org/10.1186/s12977-018-0451-0

Ledger S; Howe A; Turville S; Aggarwal A; Savkovic B; Ong A; Wolstein O; Boyd M; Millington M; Gorry PR; Murray JM; Symonds G, 2018, 'Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46', Journal of Gene Medicine, 20, http://dx.doi.org/10.1002/jgm.3006

Zaunders J; Howe A; Ledger S; Kelleher A; Murray J; Symonds G, 2017, '23 Knockdown of CCR5 expression in antigen-specific cytotoxic CD4 T cells', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30728-7

Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G, 2015, 'CCR5 targeted cell therapy for hiv and prevention of viral escape', Viruses, 7, pp. 4186 - 4203, http://dx.doi.org/10.3390/v7082816

Savkovic B; Nichols J; Birkett D; Applegate T; Ledger S; Symonds G; Murray JM, 2014, 'A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells', PLoS Computational Biology, 10, http://dx.doi.org/10.1371/journal.pcbi.1003681

Back to profile page